학술논문
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
Document Type
Article
Author
Source
In Clinical Genitourinary Cancer June 2022 20(3):285-295
Subject
Language
ISSN
1558-7673